Selective blockade of protein kinase B protects the rat and human myocardium against ischaemic injury.
Protein kinase B (PKB/Akt) plays a critical role in cell survival but the investigation of its involvement has been limited by the lack of specific pharmacological agents. In this study, using novel PKB inhibitors (VIII and XI), we investigated the role of PKB in cardioprotection of the rat and human myocardium, the location of PKB in relation to mitoK(ATP) channels and p38 mitogen-activated protein kinase (p38 MAPK), and whether the manipulation of PKB can overcome the unresponsiveness to protection of the diabetic myocardium. Myocardial slices from rat left ventricle and from the right atrial appendage of patients undergoing elective cardiac surgery were subjected to 90 min ischaemia/120 min reoxygenation at 37 degrees C. Tissue injury was assessed by creatine kinase (CK) released and determination of cell necrosis and apoptosis. The results showed that blockade of PKB activity caused significant reduction of CK release and cell death, a benefit that was as potent as ischaemic preconditioning and could be reproduced by blockade of phosphatidylinositol 3-kinase (PI-3K) with wortmannin and LY 294002. The protection was time dependent with maximal benefit seen when PKB and PI-3K were inhibited before ischaemia or during both ischaemia and reoxygenation. In addition, it was revealed that PKB is located downstream of mitoK(ATP) channels but upstream of p38 MAPK. PKB inhibition induced a similar degree of protection in the human and rat myocardium and, importantly, it reversed the unresponsiveness to protection of the diabetic myocardium. In conclusion, inhibition of PKB plays a critical role in protection of the mammalian myocardium and may represent a clinical target for the reduction of ischaemic injury.
Linares-Palomino
José
J
Cardiac Surgery Unit, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
Husainy
Muhammad A
MA
Lai
Vien K
VK
Dickenson
John M
JM
Galiñanes
Manuel
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D017209:Apoptosis; D003402:Creatine Kinase / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008875:Middle Aged; D015428:Myocardial Reperfusion Injury / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D009336:Necrosis; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D015221:Potassium Channels / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D012694:Serine; D013997:Time Factors; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D003402:Creatine Kinase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D015221:Potassium Channels; D047428:Protein Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D012694:Serine; D048051:p38 Mitogen-Activated Protein Kinases; C117780:mitochondrial K(ATP) channel
J Mol Cell Cardiol. 2002 Jun;34(6):661-8
12054853
Circ Res. 2000 Sep 15;87(6):460-6
10988237
Circulation. 2004 Jun 22;109(24):3042-9
15184284
Bioorg Med Chem Lett. 2005 Feb 15;15(4):905-9
15686884
Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1125-31
15142844
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
15784165
Circ Res. 2008 Aug 1;103(3):226-8
18669927
J Am Coll Cardiol. 2001 Mar 1;37(3):711-8
11693741
Circulation. 2001 Jul 17;104(3):330-5
11457753
Cardiovasc Res. 2006 Feb 1;69(2):450-8
16330008
Cardiovasc Res. 2002 Aug 15;55(3):690-700
12160966
Cardiovasc Res. 2000 Jan 14;45(2):339-50
10728354
Circ Res. 2000 Aug 18;87(4):309-15
10948065
Circ Res. 2009 Jan 2;104(1):15-8
19038864
Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2402-8
16687609
Circ Res. 2004 Apr 16;94(7):960-6
14976126
J Mol Cell Cardiol. 2006 Aug;41(2):256-64
16769083
J Mol Cell Cardiol. 2008 Feb;44(2):429-34
18054038
Circulation. 2008 May 27;117(21):2761-8
18490522
Tumour Biol. 1996;17(6):354-61
8938951
Cell Signal. 2008 Jan;20(1):21-30
17716864
BMC Physiol. 2002 Jul 18;2:10
12123527
Science. 1999 Nov 26;286(5445):1741-4
10576742
PLoS Biol. 2009 Jan 20;7(1):e17
19166270
Cardiovasc Res. 2006 Oct 1;72(1):152-62
16901477
Cardiovasc Res. 2004 Feb 15;61(3):427-36
14962474
J Med Chem. 2006 Jun 29;49(13):3800-8
16789737
Am J Physiol Regul Integr Comp Physiol. 2009 Apr;296(4):R972-8
19211725
Basic Res Cardiol. 2002 Jul;97(4):276-85
12111037
Circ Res. 2008 Sep 12;103(6):643-53
18688045
J Mol Cell Cardiol. 2005 Jul;39(1):17-50
15907927
Cardiovasc Res. 2009 Nov 1;84(2):173-5
19713282
Cell. 2007 Jun 29;129(7):1261-74
17604717
FASEB J. 2003 Jul;17(10):1355-7
12759340
Circ Res. 2005 Sep 16;97(6):583-6
16100048
FASEB J. 2006 Dec;20(14):2556-8
17077284
Am J Physiol Cell Physiol. 2004 Nov;287(5):C1418-25
15294852
Biochem J. 2008 Nov 1;415(3):333-44
18842113
J Mol Cell Cardiol. 2009 Jun;46(6):858-66
19118560
Curr Cancer Drug Targets. 2008 Feb;8(1):7-18
18288939
EMBO J. 2003 Sep 15;22(18):4666-76
12970179
Basic Res Cardiol. 2009 Jul;104(4):412-23
19198917
Circulation. 2008 Nov 4;118(19):1915-9
18981312
Circ Res. 2008 Aug 1;103(3):307-14
18583716
J Mol Cell Cardiol. 2005 Jan;38(1):63-71
15623422
Clin Sci (Lond). 2000 Nov;99(5):443-53
11052925
J Clin Invest. 2004 Jun;113(11):1535-49
15173880
Pharmacol Ther. 2007 Nov;116(2):173-91
17681609
Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2606-11
15331366
Cardiovasc Res. 2004 Aug 1;63(2):305-12
15249188
J Biol Chem. 1998 Jan 23;273(4):2161-8
9442057